Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of omalizumab on markers of impairment in patients with
inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in
the 2007 National Heart, Lung, and Blood Institute (NHBLI) Guidelines